Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;241(8):1663-1678.
doi: 10.1007/s00213-024-06588-8. Epub 2024 Apr 18.

N-(3-((3-(trifluoromethyl)phenyl)selanyl)prop-2-yn-1-yl) benzamide induces antidepressant-like effect in mice: involvement of the serotonergic system

Camila Simões Pires  1 , Marcia Juciele da Rocha  1 , Marcelo Heinemann Presa  1 , Narryman Pinto Zuge  1 , Natália Emanuele Biolosor Kuntz  2 , Benhur Godoi  2 , Cristiani Folharini Bortolatto  3 , César Augusto Brüning  4
Affiliations

N-(3-((3-(trifluoromethyl)phenyl)selanyl)prop-2-yn-1-yl) benzamide induces antidepressant-like effect in mice: involvement of the serotonergic system

Camila Simões Pires et al. Psychopharmacology (Berl). 2024 Aug.

Abstract

Rationale: Major Depressive Disorder (MDD) significantly impairs the quality of life for those affected. While the exact causes of MDD are not fully understood, the deficit of monoamines, especially serotonin and noradrenaline, is widely accepted. Resistance to long-term treatments and adverse effects are often observed, highlighting the need for new pharmacological therapies. Synthetic organic compounds containing selenium have exhibited pharmacological properties, including potential antidepressant effects.

Objective: To evaluate the antidepressant-like effect of N-(3-((3-(trifluoromethyl)phenyl)selenyl)prop-2-yn-1-yl) benzamide (CF3SePB) in mice and the involvement of the serotonergic and noradrenergic systems.

Methods: Male Swiss mice were treated with CF3SePB (1-50 mg/kg, i.g.) and 30 min later the forced swimming test (FST) or tail suspension test (TST) was performed. To investigate the involvement of the serotonergic and noradrenergic systems in the antidepressant-like effect of CF3SePB, mice were pre-treated with p-CPA (a 5-HT depletor, 100 mg/kg, i.p.) or the receptor antagonists WAY100635 (0.1 mg/kg, s.c., a 5-HT1A receptor antagonist), ketanserin (1 mg/kg, i.p., a 5-HT2A/2C receptor antagonist), ondansetron (1 mg/kg, i.p., a 5-HT3 receptor antagonist), GR110838 (0.1 mg/kg, i.p., a 5-HT4 receptor antagonist), prazosin (1 mg/kg, i.p., an α1-adrenergic receptor antagonist), yohimbine (1 mg/kg, i.p., an α2-adrenergic receptor antagonist) and propranolol (2 mg/kg, i.p., a non-selective beta-adrenergic receptor antagonist) at specific times before CF3SePB (50 mg/kg, i.g.), and after 30 min of CF3SePB administration the FST was performed.

Results: CF3SePB showed an antidepressant-like effect in both FST and TST and this effect was related to the modulation of the serotonergic system, specially the 5-HT1A and 5-HT3 receptors. None of the noradrenergic antagonists prevented the antidepressant-like effect of CF3SePB. The compound exhibited a low potential for inducing acute toxicity in adult female Swiss mice.

Conclusion: This study pointed a new compound with antidepressant-like effect, and it could be considered for the development of new antidepressants.

Keywords: Benzamide; Depression; Mice; Noradrenergic system; Selenium; Serotonergic system.

PubMed Disclaimer

References

    1. Akil H, Gordon J, Hen R, Javitch J, Mayberg H, McEwen B, Meaney MJ, Nestler EJ (2018) Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev 84:272–288. https://doi.org/10.1016/j.neubiorev.2017.08.019 - DOI - PubMed
    1. Anghinoni JM, Birmann PT, da Rocha MJ, Gomes CS, Davies MJ, Brüning CA, Savegnago L, Lenardão EJ (2023) Recent advances in the synthesis and antioxidant activity of low molecular Mass Organoselenium. Molecules Molecules 28(21):7349. https://doi.org/10.3390/molecules28217349 - DOI - PubMed
    1. Artigas F (2015) Developments in the field of antidepressants, where do we go now? Eur Neuropsychopharmacol 25:657–670. https://doi.org/10.1016/j.euroneuro.2013.04.013 - DOI - PubMed
    1. Asif M (2016) Pharmacological potential of benzamide analogues and their uses in medicinal chemistry. Modern Chem Appl 4(4). https://doi.org/10.4172/2329-6798.1000194
    1. Assie MB, Bardin L, Auclair AL, Carilla-Durand E, Depoortere R, Koek W, Kleven MS, Colpaert F, Vacher B, Newman-Tancredi A (2010) F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in vivo profile in behavioural models of antidepressant and serotonergic activity. Int J Neuropsychopharmacol 13:1285–1298. https://doi.org/10.1017/S1461145709991222 - DOI - PubMed

LinkOut - more resources